Seamus Mulligan was founder, Chairman, and Chief Executive Officer of Adapt Pharma Limited, which developed Narcan® Nasal Spray, for the treatment of suspected opioid overdose.  Adapt was acquired by Emergent BioSolutions in 2018.  Prior to Adapt Pharma, Seamus founded and was Chairman and Chief Executive Officer of Azur Pharma, a CNS and Women’s Health pharmaceutical business, which merged with Jazz Pharmaceuticals plc, in 2012. Seamus serves on the Board of Directors at Jazz Pharmaceuticals.

Over a 20-year period prior to founding Azur Pharma, Seamus was closely involved with Élan Corporation’s growth and evolution from a drug delivery company into a research-focused pharmaceutical organization. Seamus holds a Bachelor of Science in Pharmaceuticals and a Master of Science from Trinity College, Dublin, Ireland.

Mr David Brabazon was a co-founder and served as Chief Financial Officer of Adapt Pharma Limited, which developed Narcan Nasal Spray, for the treatment of suspected opioid overdose.  Adapt was acquired by Emergent BioSolutions in 2018.  Mr Brabazon was a co-founder and Chief Financial Officer of Azur Pharma plc, which merged with Jazz Pharmaceuticals plc in early 2012. Prior to Azur Pharma, Mr Brabazon served as Vice President of Finance and Group Financial Controller of Elan Corporation plc.

Mr Brabazon is a chartered accountant and holds a Master of Accounting degree from University College Dublin, Ireland and a Master of Business Administration degree from INSEAD, France.  Mr Brabazon serves as a director of Mainstay Medical – a medical device company.

Mr Eunan Maguire was a co-founder and served as Chief Operating Officer of Adapt Pharma Limited, which developed Narcan Nasal Spray, for the treatment of suspected opioid overdose.  Adapt was acquired by Emergent BioSolutions in 2018.  Eunan was also a co-founder and President of Azur Pharma – a CNS and Women’s Health pharmaceutical business – which merged with Jazz Pharmaceuticals plc in early 2012. He subsequently led strategy and corporate development at Jazz until 2013.  Earlier in his career, Eunan served as Vice President of business development at King Pharmaceuticals (acquired by Pfizer) and Vice President of Strategy at Elan Corporation.

Eunan is a chartered accountant by profession and holds a Bachelor of International Commerce and French from University College Dublin, Ireland.  Eunan serves as a director of Avectas Limited – a cell engineering business, and ONK Therapeutics – a Natural Killer focused cell therapy business.

Mr Declan Brides previously served as vice president of finance for Adapt Pharma and more recently served as vice president of finance for Emergent BioSolutions, following its acquisition of Adapt Pharma in 2018. Whilst in this role, he also served as a member of the Emergent BioSolutions Device Business Unit Leadership Team. Prior to Adapt Pharma, he worked with KPMG in both Ireland and New York, primarily providing audit services to US-listed entities and private Irish entities operating in the pharmaceutical sector.

Mr Brides is a chartered accountant by profession and holds a Bachelor of Engineering in Mechanical Engineering from University College Dublin.

Mr Fintan Keegan was a co-founder and served as Chief Technical Officer of Adapt Pharma Limited, which developed Narcan Nasal Spray, for the treatment of suspected opioid overdose. Adapt was acquired by Emergent BioSolutions in 2018. Previously Mr Keegan was head of Technical Operations at Azur Pharma and served as Executive Vice President of Technical Operations at Jazz Pharmaceuticals, plc after its merger with Azur Pharma plc in early 2012.

Fintan has broad experience including Vice President of Quality and Regulatory for Elan Corporation. Previously, he held positions with Wyeth Pharmaceuticals, Inc., Merck & Co, Inc. and at a clinical contract research organization.

Fintan holds a B.Sc and a H. Dip in Pharmaceutical Manufacturing Technology from Trinity College Dublin and a M.Sc from the School of Chemistry, University of Bristol, in the United Kingdom.